Growth, motor, and social development in breast- and formula-fed infants of metformin-treated women with polycystic ovary syndrome
Objectives
To test the hypothesis that metformin during lactation versus formula feeding would have no adverse effects on infants’ growth, motor-social development, or intercurrent illness.
Study design
Growth, motor-social development, and illness requiring a pediatrician visit were assessed in 61 nursing infants (21 male, 40 female) and 50 formula-fed infants (19 male, 31 female) born to 92 mothers with polycystic ovary syndrome (PCOS) taking a median of 2.55 g metformin per day throughout pregnancy and lactation.
Results
Within sex, at 3 and 6 months of age, weight, height, and motor-social development did not differ (p ≥.06) between breast- and formula-fed infants. No infants had retardation of growth, motor, or social development. Intercurrent illnesses did not differ.
Conclusions
Metformin during lactation appears to be safe and effective in the first 6 months of infancy.
Abbreviations: PCOS, Polycystic ovary syndrome
To access this article, please choose from the options below
Supported by the Jewish Hospital Lipoprotein Research Fund and by the Medical Research Council of the Jewish Hospital.
PII: S0022-3476(06)00013-8
doi:10.1016/j.jpeds.2006.01.011
© 2006 Elsevier Inc. All rights reserved.
Refers to article:
- Expanding applications for metformin in polycystic ovarian syndrome
